Table 4 Short-acting β-agonist prescriptions
| Â | 6 months prior | On index date | 12 months after |
|---|---|---|---|
No. prescriptions, median (range) | 1 (1-13) | 1 (1-3) | 2 (1-26) |
Patients with prescriptions, by controller therapy, n (%) | |||
ICS monotherapy (n = 9059) | 2805 (31.0)* | 6876 (75.9)* | 6515 (71.9)* |
ICS + LABA (n = 698) | 174 (24.9) | 497 (71.2) | 519 (74.4) |
ICS + LTRA (n = 55) | 13 (23.6) | 44 (80.0) | 49 (89.1) |
LTRA monotherapy (n = 91) | 38 (41.8) | 30 (33.0) | 69 (75.8) |
Other (n = 101) | 31 (30.7) | 62 (61.4) | 82 (81.2) |
Total (n = 10,004) | 3061 (30.6) | 7509 (75.1) | 7234 (72.3) |
Survey cohort: patients with prescriptions, by asthma severity, n (%) | |||
Intermittent (n = 346) | 87 (25.1)* | 274 (79.2) | 241 (69.7)* |
Mild persistent (n = 159) | 57 (35.9) | 118 (74.2) | 129 (81.1) |
Moderate persistent (n = 71) | 30 (42.3) | 52 (73.2) | 62 (87.3) |
Severe persistent (n = 11) | 6 (54.6) | 9 (81.8) | 9 (81.8) |
Missing classification (n = 48) | 13 (27.1) | 31 (64.6) | 36 (75.0) |
Total (n = 635) | 193 (30.4) | 484 (76.2) | 477 (75.1) |